^
Association details:
| Biomarker: | CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | BMS‐986504 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Published date:
11/01/2023
Excerpt:
A 73-year-old male diagnosed with BRAF WT, stage IV melanoma...Targeted NGS demonstrated a homozygous CDKN2A/B/MTAP deletion and TERT mutation….The patient was administered MRTX1719 100 mg q.d. p.o. on a 21-day cycle and a slow decrease in all lesions, including a RECIST-defined partial response of 30% reduction of the splenic lesion that was observed at cycle 7 day 1. Subsequent disease assessments at cycle 9 day 1 and cycle 14 day 1 demonstrated continued response, with a 40% reduction of the splenic lesion in the latest assessment...
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0669
